1-20 of 36 results for subject:"Medical treatments"
Librarians' tools
- Search time
- 0.281 seconds
- Solr query time
- 0.008 seconds
- Search query
- subject:"Medical treatments"
- We searched for
- subject_t:"Medical treatments" OR subject_ses:91973
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health how many medical procedures had been undertaken in respect of NHS patients in each wave 1 independent sector treatment centre on the latest date for which figures are available.
To ask the Secretary of State for Health how many medical procedures had been undertaken in respect of NHS patients in each wave 1 independent sector treatment centre on the latest date for which figures are available.
| Treatment centre name | Provider name | Procedures (discharges) | Diagnostic procedures | Primary care episodes |
| Eccleshill NHS Treatment Centre | Nations Healthcare | 25,775 | 106,090 | 0 |
| Midlands NHS Treatment Centre | Nations Healthcare | 28,420 | 0 | 0 |
| Barlborough NHS Treatment Centre | PHG | 18,217 | 0 | 0 |
| Shepton Mallet NHS Treatment Centre | UKSH | 38,856 | 0 | 0 |
| Greater Manchester Surgical Centre | Netcare Healthcare | 24,061 | 0 | 0 |
| Peninsula NHS Treatment Centre | PHG | 15,282 | 0 | 0 |
| Bodmin NHS Treatment Centre | Ramsay | 14,911 | 0 | 0 |
| Boston NHS Treatment Centre | Ramsay | 5,618 | 762 | 0 |
| Clifton Park NHS Treatment Centre | Ramsay | 10,797 | 0 | 0 |
| The Cobalt NHS Treatment Centre | Ramsay | 9,751 | 0 | 0 |
| Gainsborough NHS Treatment Centre | Ramsay | 3,667 | 0 | 0 |
| New Hall NHS Treatment Centre | Ramsay | 8,318 | 0 | 0 |
| Horton NHS Treatment Centre | Ramsay | 9,654 | 0 | 0 |
| Blakelands NHS Treatment Centre | Ramsay | 7,370 | 0 | 0 |
| Reading NHS Treatment Centre | Ramsay | 5,258 | 0 | 0 |
| Nottingham NHS Treatment Centre at QMC | Nations Healthcare | 29,637 | 0 | 0 |
| Cheshire and Merseyside NHS Treatment Centre | Interhealth | 17,098 | 0 | 0 |
| Kidderminster NHS Treatment Centre | Interhealth | 9,299 | 0 | 0 |
| Mid Kent NHS Treatment Centre | PHG | 23,100 | 25,969 | 0 |
| North East London NHS Treatment Centre | PHG | 21,512 | 0 | 0 |
| Sussex Orthopaedic NHS Treatment Centre | Care UK | 18,026 | 0 | 0 |
| Havant NHS Diagnostic Centre | Care UK | 11 | 21,539 | 0 |
| Will Adams NHS Treatment Centre | Care UK | 11,611 | 0 | 2,538 |
| St. Mary's NHS Treatment Centre | Care UK | 19,487 | 78,722 | 182,657 |
| Mid and South Buckinghamshire NHS Diagnostic Centre | Care UK | 0 | 56,249 | 0 |
| Total | 375,736 | 289,331 | 185,195 |
To ask the Secretary of State for Health when he expects to publish his Department's response to its consultation on the proposed transfer of responsibility for commissioning ultra-orphan treatments from the National Institute for Health and Clinical Excellence to the National Specialised Commissioning Group.
To ask the Secretary of State for Health when he expects to publish his Department's response to its consultation on the proposed transfer of responsibility for commissioning ultra-orphan treatments from the National Institute for Health and Clinical Excellence to the National Specialised Commissioning Group.
To ask the Secretary of State for Health whether primary care trusts are required to provide funding for clinical decisions and medicines included within recommendations by the National Institute of Health and Clinical Excellence contained in Technology Appraisal Guidance; and under what circumstances a primary care trust may decide not...
To ask the Secretary of State for Health whether primary care trusts are required to provide funding for clinical decisions and medicines included within recommendations by the National Institute of Health and Clinical Excellence contained in Technology Appraisal Guidance; and under what circumstances a primary care trust may decide not...
To ask the Secretary of State for Health when he expects the National Institute for Health and Clinical Excellence to publish its response to the consultation on its response to Sir Ian Kennedy's report on Appraising the Value of Innovation.
To ask the Secretary of State for Health when he expects the National Institute for Health and Clinical Excellence to publish its response to the consultation on its response to Sir Ian Kennedy's report on Appraising the Value of Innovation.
To ask the Secretary of State for Health whether Evidence Review Groups are required to complete their assessments within the timetables set by the National Institute for Health and Clinical Excellence for (a) multiple and (b) single technology appraisals.
To ask the Secretary of State for Health whether Evidence Review Groups are required to complete their assessments within the timetables set by the National Institute for Health and Clinical Excellence for (a) multiple and (b) single technology appraisals.
To ask the Secretary of State for Health what the average waiting time for all treatments was in each year since 1997.
To ask the Secretary of State for Health what the average waiting time for all treatments was in each year since 1997.
| In-patient waiting times—commissioner based | |
|---|---|
| As at March each year | Median wait (weeks) |
| 1997 | 13.2 |
| 1998 | 14.9 |
| 1999 | 12.9 |
| 2000 | 12.9 |
| 2001 | 12.6 |
| 2002 | 12.7 |
| 2003 | 11.9 |
| 2004 | 10.2 |
| 2005 | 8.5 |
| 2006 | 7.3 |
| 2007 | 6.2 |
| 2008 | 4.5 |
| 2009 | 4.0 |
| Notes: | |
| 1. Figures shown relate to March each year, and are a snapshot of the median wait of patients waiting at the end of each period. The latest data available are for January 2010, and this figure shows the median wait of those still waiting at the end of that month of 5.0 weeks. March 2010 data will be published on 30 April 2010 | |
| 2. It should be noted that median waits in the winter months historically tend to be higher than other months. We would therefore expect the median at March 2010 to be lower than five weeks as shown in January 2010. | |
| Source: | |
| Department, of Health, QF01, MMRCOM |
To ask the Secretary of State for Health (1) what assessment he has made of the effect of the end of life criteria used by the National Institute for Health and Clinical Excellence on the level of patient access to treatments for rarer cancers;
To ask the Secretary of State for Health (1) what assessment he has made of the effect of the end of life criteria used by the National Institute for Health and Clinical Excellence on the level of patient access to treatments for rarer cancers;
(2) whether his Department provides guidance to National Institute for Health and Clinical Excellence appraisal committees on the application of its end of life criteria.
(2) whether his Department provides guidance to National Institute for Health and Clinical Excellence appraisal committees on the application of its end of life criteria.
To ask the Secretary of State for Health what recent discussions he has had with the National Institute for Health and Clinical Excellence on its Health Technology Appraisal process in respect of rarer cancers.
To ask the Secretary of State for Health what recent discussions he has had with the National Institute for Health and Clinical Excellence on its Health Technology Appraisal process in respect of rarer cancers.
To ask the Secretary of State for Health what recent assessment he has made of the health effects of low level laser therapy.
To ask the Secretary of State for Health what recent assessment he has made of the health effects of low level laser therapy.
Westminster Hall adjournment debate on multiple sclerosis risk sharing drugs.
Westminster Hall adjournment debate on multiple sclerosis risk sharing drugs.
Adjournment debate on diagnosis of prostate cancer and trials of the drug abiraterone.
Adjournment debate on diagnosis of prostate cancer and trials of the drug abiraterone.
To ask the Secretary of State for Health what the net expenditure per 100,000 unified weighted population was for each primary care trust on treatment for (a) cancer and tumours and (b) mental health in each year since 2003-04.
To ask the Secretary of State for Health what the net expenditure per 100,000 unified weighted population was for each primary care trust on treatment for (a) cancer and tumours and (b) mental health in each year since 2003-04.
To ask the Secretary of State for Health what ex-gratia payments have been made by his Department to (a) persons adversely affected by thalidomide and (b) other NHS patients who have been adversely affected by NHS treatment.
To ask the Secretary of State for Health what ex-gratia payments have been made by his Department to (a) persons adversely affected by thalidomide and (b) other NHS patients who have been adversely affected by NHS treatment.
To ask the Secretary of State for Health what representations his Department has received on the operation of the National Institute for Health and Clinical Excellence's supplementary advice on appraising treatments which may extend life, at the end of life, since 17 December 2008; and if he will make a...
To ask the Secretary of State for Health what representations his Department has received on the operation of the National Institute for Health and Clinical Excellence's supplementary advice on appraising treatments which may extend life, at the end of life, since 17 December 2008; and if he will make a...
To ask the Secretary of State for Health what medication the National Institute for Health and Clinical Excellence is assessing in relation to the treatment of complex regional pain syndrome.
To ask the Secretary of State for Health what medication the National Institute for Health and Clinical Excellence is assessing in relation to the treatment of complex regional pain syndrome.
To ask the Secretary of State for Health what research his Department has commissioned into the merits of including societal costs and benefits within technology appraisals made by the National Institute for Health and Clinical Excellence; and if he will make a statement.
To ask the Secretary of State for Health what research his Department has commissioned into the merits of including societal costs and benefits within technology appraisals made by the National Institute for Health and Clinical Excellence; and if he will make a statement.
To ask the Secretary of State for Health (1) what assessment he has made of regional variations in the availability of treatments for rheumatoid arthritis approved by the National Institute for Health and Clinical Excellence;
To ask the Secretary of State for Health (1) what assessment he has made of regional variations in the availability of treatments for rheumatoid arthritis approved by the National Institute for Health and Clinical Excellence;